C170 (Darifenacin hydrobromide extended-release 7.5 mg (base))

Pill imprint C170 has been identified as Darifenacin hydrobromide extended-release 7.5 mg (base).

Darifenacin is used in the treatment of urinary incontinence; overactive bladder and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Darifenacin 7.5 mg (base) is not a controlled substance under the Controlled Substance Act (CSA).

Darifenacin hydrobromide extended-release

Imprint:

C170

Strength:

7.5 mg (base)

Color:

Yellow

Shape:

Round

Availability:

Prescription only

Drug Class:

Urinary antispasmodics

Pregnancy Category:

C - Risk cannot be ruled out

CSA Schedule:

Not a controlled drug

Manufacturer:

Par Pharmaceutical, Inc.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.